Patents by Inventor Haruo Sugano

Haruo Sugano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9376478
    Abstract: Disclosed is a recombinant plasmid having a gene which encompasses at least the entire coding region of human fibroblast interferon messenger RNA and a method for preparing such plasmid.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 28, 2016
    Assignee: JURIDICAL FOUNDATION, JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Haruo Sugano, Masami Muramatsu, Tadatsugu Taniguchi
  • Publication number: 20030022878
    Abstract: Catechins, known to be components of tea, can inhibit the enzyme activity of telomerase, an enzyme that synthesizes the telomeric DNA which is responsible for stabilizing the chromosome during cell growth. This telomerase inhibiting activity showed the usefulness of catechins as a cancer prevention agent, an anticancer agent, or a cancer retardation agent, or the like.
    Type: Application
    Filed: December 28, 1998
    Publication date: January 30, 2003
    Inventors: TAKASHI TSURUO, NAASANI IMAD, HIROYUKI SEIMIYA, HARUO SUGANO
  • Publication number: 20010041362
    Abstract: A gene coded for a polypeptide which possesses interleukin-2 is isolated, and connected with a vector DNA which is capable of replicating in a procaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombant DNA, with which the cell is transformed to produce interleukin-2.
    Type: Application
    Filed: January 26, 2001
    Publication date: November 15, 2001
    Applicant: AJINOMOTO CO., INC.
    Inventors: Tadatsugu Taniguchi, Masami Muramatsu, Haruo Sugano, Hiroshi Matsui, Nobukazu Kashima, Junji Hamuro
  • Patent number: 5795769
    Abstract: A gene coded for a polypeptide which possesses interleukin-2 is isolated, and connected with a vector DNA which is capable of replicating in a procaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombinant DNA, with which the cell is transformed to produce interleukin-2.
    Type: Grant
    Filed: August 18, 1995
    Date of Patent: August 18, 1998
    Assignee: Ajinomoto Co. Inc.
    Inventors: Tadatsugu Taniguchi, Masami Muramatsu, Haruo Sugano, Hiroshi Matsui, Nobukazu Kashima
  • Patent number: 5795777
    Abstract: A gene coded for a polypeptide which possesses interleukin-2 is isolated, and connected with a vector DNA which is capable of replicating in a procaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombinant DNA, with which the cell is trans-formed to produce interleukin-2.
    Type: Grant
    Filed: March 22, 1996
    Date of Patent: August 18, 1998
    Assignee: Ajinomoto Co., Inc.
    Inventors: Tadatsugu Taniguchi, Masami Muramatsu, Haruo Sugano, Hiroshi Matsui, Nobukazu Kashima, Junji Hamuro
  • Patent number: 5700913
    Abstract: Recombinant human Interleukin-2 (IL-2) polypeptides are provided. The polypeptides are produced by expression of suitable nucleic acid molecules in transformed host cells such as E. coli.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: December 23, 1997
    Assignees: Ajinomoto Co., Inc., Japanese Foundation for Cancer Research
    Inventors: Tadatsugu Taniguchi, Masami Muramatsu, Haruo Sugano, Hiroshi Matsui, Nobukazu Kashima, Junji Hamuro
  • Patent number: 5620868
    Abstract: A gene coded for a polypeptide which possesses interleukin-2 is isolated, and connected with a vector DNA which is capable of replicating in a procaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombinant DNA, with which the cell is transformed to produce interleukin-2.
    Type: Grant
    Filed: December 26, 1991
    Date of Patent: April 15, 1997
    Assignees: Ajinomoto Co., Inc., Japanese Foundation for Cancer Research
    Inventors: Tadatsugu Taniguchi, Masami Muramatsu, Haruo Sugano, Hiroshi Matsui, Nobukazu Kashima, Junji Hamuro
  • Patent number: 5514567
    Abstract: Disclosed is a recombinant plasmid having a gene which encompasses at least the entire coding region of human fibroblast interferon messenger RNA and a method for preparing such plasmid.
    Type: Grant
    Filed: March 6, 1995
    Date of Patent: May 7, 1996
    Assignee: Juridical Foundation, Japanese Foundation For Cancer Research
    Inventors: Haruo Sugano, Masami Muramatsu, Tadatsugu Taniguchi
  • Patent number: 5399669
    Abstract: Recombinantly produced interleukin-2 exhibits human IL-2 activity, has a molecular weight of about 15,000 daltons, is activity stable at a pH of 2-9 and is resistant to elevated temperatures. The recombinant IL-2 has the principal biological activity of human IL-2, promotion of proliferation of cytotoxic T lymphocytes.
    Type: Grant
    Filed: July 26, 1993
    Date of Patent: March 21, 1995
    Assignees: Ajinomoto Co., Inc., Japanese Foundation For Cancer Research
    Inventors: Tadatsugu Taniguchi, Masami Muramatsu, Haruo Sugano, Hiroshi Matsui, Nobukazu Kashima, Junji Hamuro
  • Patent number: 5326859
    Abstract: Disclosed is a recombinant plasmid having a gene which encompasses at least the entire coding region of human fibroblast interferon messenger RNA and a method for preparing such plasmid.
    Type: Grant
    Filed: October 27, 1980
    Date of Patent: July 5, 1994
    Assignee: Juridical Foundation, Japanese Foundation for Cancer Research
    Inventors: Haruo Sugano, Masami Muramatsu, Tadatsugu Taniguchi
  • Patent number: 5087560
    Abstract: Monoclonal antibodies are disclosed that may be produced by hybridomas obtained by fusing a mouse spleen cell immunized with an ADRIAMYCIN.RTM.-resistant human tumor cell and a mouse myeloma cell and which inhibit selectively the growth of cancer cells possessing pleiotropic drug resistance or enhance their sensitivity to said drug.
    Type: Grant
    Filed: October 1, 1990
    Date of Patent: February 11, 1992
    Assignee: Japanese Foundation for Cancer Research
    Inventors: Takashi Tsuruo, Hirofumi Hamada, Haruo Sugano
  • Patent number: 4835256
    Abstract: Disclosed is a novel DNA which shows complementarity to human interferon-.gamma. mRNA, a recombinant plasmid containing the DNA, a microorganism containing the recombinant plasmid and a method of producing the same as well as a process for producing a polypeptide having human interferon.gamma. activity using the microorganism.
    Type: Grant
    Filed: December 3, 1987
    Date of Patent: May 30, 1989
    Assignees: New York University & Juridical Foundation, Japanese Foundation for Cancer Research
    Inventors: Tadatsugu Taniguchi, Haruo Sugano, Tatsunari Nishi, Jan T. Vilcek, Yum K. Yip
  • Patent number: 4804746
    Abstract: An antibody of a human leukemia virus-related peptide obtained by collecting an antibody produced in a mammal body by administering to the mammal an antigen prepared by reacting a human leukemia virus-related peptide selected from the group consisting of:(a) a peptide represented by formula (1):H-Tyr-Val-Glu-Pro-Thr-Ala-Pro-Gln-Val-Leu-H (1)(b) a peptide represented by formula (2): psR-Ile-Pro-His-Pro-Lys-Asn-Ser-Ile-Gly-Gly-Glu-Val-OH (2)wherein R is the same as defined above;(c) a peptide represented by formula (3):R-Thr-Trp-Thr-Pro-Lys-Asp-Lys-Thr-Lys-Val-Leu-OH (3)wherein R is the same as defined above;(d) a peptide represented by formula (4):H-Val-Val-Gln-Pro-Lys-Lys-Pro-Pro-Pro-Tyr-OH (4)(e) a peptide represented by formula (5):R-Met-Gly-Gln-Ile-Phe-Ser-Arg-Ser-Ala-Ser-Pro-OH (5)wherein R is the same as defined above; and(f) a peptide represented by formula (6):H-Tyr-Pro-Glu-Gly-Thr-Pro-Lys-Asp-Pro-Ile-Leu-Arg-Ser-Leu-OH (6)as a hapten, with a carrier in the presence of a haptencarrier binding agent.
    Type: Grant
    Filed: March 19, 1985
    Date of Patent: February 14, 1989
    Assignees: Japanese Foundation for Cancer Research, Otsuka Pharmaceutical Co., Ltd.
    Inventors: Mitsuaki Yoshida, Haruo Sugano, Fumio Shimizu, Kenichi Imagawa
  • Patent number: 4795805
    Abstract: Recombinant plasmids are constructed by inserting a DNA fragment coding for a fused protein of an adult T cell leukemia virus antigen peptide and an enzyme into a vector DNA. Microorganisms are transformed with the recombinant plasmid and thereafter cultured to express the fused protein. The fused protein is useful for the detection and diagnosis of adult T cell leukemia.
    Type: Grant
    Filed: October 2, 1987
    Date of Patent: January 3, 1989
    Assignees: Kyowa Hakko Kogyo Co., Ltd., Juridical Foundation, Japanese Foundation for Cancer Research
    Inventors: Seiga Itoh, Susumu Sekine, Tadatsugu Taniguchi, Mitsuaki Yoshida, Haruo Sugano
  • Patent number: 4778756
    Abstract: A viral genomic DNA and fragments thereof which are complementary to genomic RNA of human leukemia virus and a recombinant DNA molecules containing the genomic DNA or fragments thereof. The genomic DNA and fragments thereof and the recombinant DNA molecules are useful for the diagnosis, prevention and therapy of human leukemia.
    Type: Grant
    Filed: October 5, 1987
    Date of Patent: October 18, 1988
    Assignee: Juridical Foundation, Japanese Foundation for Cancer Research
    Inventors: Mitsuaki Yoshida, Haruo Sugano
  • Patent number: 4738931
    Abstract: The present invention relates to human interferon-.beta. gene derived from human chromosome, a DNA containing said gene and a DNA responsible for control of its transcription and a recombinant DNA of said DNA and a vector DNA. The gene and DNA of the present invention are introduced in eukaryotic cells and used for the production of human interferon-.beta..
    Type: Grant
    Filed: July 6, 1987
    Date of Patent: April 19, 1988
    Assignee: Juridical Foundation, Japanese Foundation for Cancer Research
    Inventors: Haruo Sugano, Tadatsugu Taniguchi, Shigeo Ono
  • Patent number: 4738927
    Abstract: A gene coded for a polypeptide which possesses interleukin-2 activity is isolated, and connected with a vector DNA which is capable of replicating in a procaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombinant DNA, with which the cell is transformed to produce interleukin-2.
    Type: Grant
    Filed: February 3, 1983
    Date of Patent: April 19, 1988
    Assignee: Ajinomoto Co. Inc.
    Inventors: Tadatsugu Taniguchi, Masami Muramatsu, Haruo Sugano, Hiroshi Matsui, Nobukazu Kashima, Junji Hamuro
  • Patent number: 4724258
    Abstract: Recombinant plasmids are constructed by inserting a DNA fragment containing the env gene of adult T cell leukemia virus or a part thereof into a vector DNA. Microorganisms are transformed with the recombinant plasmid and thereafter cultured to express the peptide. The antigen polypeptide encoded by the env gene is useful for the detection and diagnosis of adult T cell leukemia.
    Type: Grant
    Filed: January 29, 1985
    Date of Patent: February 9, 1988
    Assignee: Juridical Foundation, Japanese Foundation for Cancer Research
    Inventors: Mitsuaki Yoshida, Haruo Sugano
  • Patent number: 4686191
    Abstract: Recombinant vector plasmids containing a DNA fragment coding for human interferon-.beta. inserted downstream from a tryptophan promoter are useful for transformation of microorganisms such as Escherichia coli which transformants produce human interferon-.beta..
    Type: Grant
    Filed: December 22, 1982
    Date of Patent: August 11, 1987
    Assignees: Hakko Kogyo Co., Ltd. Kyowa, Juridical Foundation, Japanese Foundation for Cancer Research
    Inventors: Seiga Itoh, Tatsunari Nishi, Tamio Mizukami, Tadashi Matsumoto, Tetsuo Oka, Tadatsugu Taniguchi, Haruo Sugano
  • Patent number: 4525300
    Abstract: An antibody of a human leukemia virus-related peptide obtained by collecting an antibody produced in a mammal body by administering to the mammal an antigen prepared by reacting a human leukemia virus-related peptide selected from the group consisting of:(a) a peptide represented by formula (1):H-Tyr-Val-Glu-Pro-Thr-Ala-Pro-Gln-Val-Leu-H (1)(b) a peptide represented by formula (2):R-Ile-Pro-His-Pro-Lys-Asn-Ser-Ile-Gly-Gly-Glu-Val-OH (2)wherein R is the same as drefined above;(c) a peptide represented by formula (3):R-Thr-Trp-Thr-Pro-Lys-Asp-Lys-Thr-Lys-Val-Leu-OH (3)wherein R is the same as defined above;(d) a peptide represented by formula (4):H-Val-Val-Gln-Pro-Lys-Lys-Pro-Pro-Pro-Tyr-OH (4)(e) a peptide represented by formula (5):R-Met-Gly-Gln-Ile-Phe-Ser-Arg-Ser-Ala-Ser-Pro-OH (5)wherein R is the same as defined above; and(f) a peptide represented by formula (6):H-Tyr-Pro-Glu-Gly-Thr-Pro-Lys-Asp-Pro-Ile-Leu-Arg-Ser-Leu-OH (6)as a hapten, with a carrier in the presence of a hapten-carrier binding agent.
    Type: Grant
    Filed: September 23, 1983
    Date of Patent: June 25, 1985
    Assignees: Japanese Foundation for Cancer Research, Otsuka Pharmaceutical Co., Ltd.
    Inventors: Mitsuaki Yoshida, Haruo Sugano, Fumio Shimizu, Kenichi Imagawa